Global Human Insulin Market 2015-2019

About Insulin
Insulin is a hormone produced by beta cells of the pancreas that plays a key role in the regulation of blood glucose levels. It controls the body systems and regulates the uptake of amino acids by body cells. It helps cells absorb glucose from the blood. In diabetics, cells stop responding to the insulin produced. As a result, glucose in the blood cannot be absorbed by the cells of the body. This condition damages body tissues over the period of time and causes disabling and life-threatening health complications such as diabetic nephropathy and diabetic retinopathy. In type 1 diabetes, the body does not produces sufficient insulin to regulate blood glucose level. Individuals with this type of diabetes need to take insulin daily. Patients with type 2 diabetes also need doses of insulin coupled with medication. Different types of insulin such as human insulin and insulin analogs are available as insulin replacement therapy. 

Technavio's analysts forecast the global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019.                      

Covered in this report
The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes. 

Technavio's report, Global Human Insulin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.

Key vendors
• Eli Lilly
• Novo Nordisk
• Sanofi

Other prominent vendors 
• Biocon
• Biodel
• Biogenomics
• Boehringer Ingelheim 
• Bristol-Myers Squibb
• Diamyd Medical 
• Diasome Pharmaceuticals
• DiaVacs 
• Pfizer 
• Generex Biotechnology 
• Lexicon Pharmaceuticals
• Macrogenics 
• Merck
• Oramed Pharmaceuticals
• Osiris Therapeutics
• Thermalin Diabetes
• Tolerion 
• Wockhardt
• XOMA Corporation

Market driver
• Increase in prevalence of diabetes
• For a full, detailed list, view our report

Market challenge
• Stringent regulatory environment
• For a full, detailed list, view our report

Market trend
• Increasing R&D for novel mechanisms
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?